1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsAdvanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) is sponsored by National Institutes of Health. Supports advanced development of informatics technologies for cancer research and management, focusing on bioinformatics and data tools.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93. 394 -- Cancer Detection and Diagnosis Research 93. 396 -- Cancer Biology Research 93.
395 -- Cancer Treatment Research 93. 393 -- Cancer Cause and Prevention Research Last Updated: May 21, 2026 View version history on Grants.
gov This Notice of Funding Opportunity (NOFO) invites applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology.
As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this NOFO is focused on advancing emerging informatics technology, defined as one that has passed the initial... prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field.
To be successful, proposed development plans must have a clear rationale for why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from driving cancer research projects as well as the broader user community throughout the development process must be included.
This NOFO invites applications for the enhancement and dissemination of emerging, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research. The emphasis is on uniqueness and potential impact on cancer research.
In addition, all projects proposed in response to this NOFO must involve the following general attributes:Potential to advance driving cancer research projects and the cancer research field in general;Offers clear advantages over competing technologies in the targeted cancer research domain;Provides compelling plans and processes for supporting and engaging end users to evaluate and apply the tool or resource;Provides plans for advancing use of the tool or resource by the targeted community through collaboration, outreach, and training;Provides a realistic timeline and milestones for technology development.
For-profit organizations other than small businesses City or township governments Federally recognized Native American tribal governments Special district governments Public and Indian housing authorities Independent school districts Public and state institutions of higher education Private institutions of higher education Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) Nonprofits non-higher education without 501(c)(3) Refer to Section III.
Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Grantor contact information Center for Strategic Scientific Initiatives (CSSI) File name Description Last updated RFA-CA-27-020-Full-Announcement. html RFA-CA-27-020-Full-Announcement.
html May 21, 2026 12:44 PM UTC Link to additional information Closing: October 19, 2026 Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Nonprofits, higher education institutions, and other eligible organizations per NIH guidelines. Confirm the full requirements in the official notice before applying.
Applications for Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) are due October 20, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) is funded by National Institutes of Health. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article